赛升药业
(300485)
| 流通市值：23.69亿 | | | 总市值：41.66亿 |
| 流通股本：2.74亿 | | | 总股本：4.82亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 180,725,174.26 | 90,438,931.64 | 404,718,439.82 | 308,627,146.45 |
| 营业收入 | 180,725,174.26 | 90,438,931.64 | 404,718,439.82 | 308,627,146.45 |
| 二、营业总成本 | 185,441,288.45 | 81,693,249.46 | 416,569,516.64 | 302,545,729.03 |
| 营业成本 | 58,115,162.9 | 28,844,515.89 | 141,187,467.33 | 106,303,657.55 |
| 税金及附加 | 4,557,966.19 | 1,054,419.98 | 9,292,106.42 | 6,198,686.6 |
| 销售费用 | 67,342,575.65 | 32,427,275.58 | 144,467,931.51 | 105,323,507.66 |
| 管理费用 | 25,611,169.33 | 11,008,646.82 | 52,961,807.92 | 37,218,652.53 |
| 研发费用 | 29,708,290.87 | 8,329,514.2 | 69,512,688.8 | 48,400,428.36 |
| 财务费用 | 106,123.51 | 28,876.99 | -852,485.34 | -899,203.67 |
| 其中:利息费用 | 430,310.25 | 67,497.4 | 454,539.03 | - |
| 其中:利息收入 | 94,693.78 | 47,827.93 | 1,012,885.32 | 901,451.74 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -141,158,344.6 | -8,069,923.06 | 8,607,096.73 | 44,588,392.93 |
| 加:投资收益 | -29,016,465.07 | 1,971,897.63 | 28,538,742.24 | 19,308,320.25 |
| 资产处置收益 | - | - | 111,881.57 | 111,881.57 |
| 资产减值损失(新) | - | - | -17,766,578.93 | -11,368,800 |
| 信用减值损失(新) | 2,137,449.51 | 753,623.26 | 943,104.79 | -657,963.36 |
| 其他收益 | 414,277.87 | 297,815.86 | 3,832,901.13 | 1,185,549.86 |
| 四、营业利润 | -172,339,196.48 | 3,699,095.87 | 12,416,070.71 | 59,248,798.67 |
| 加:营业外收入 | 778,937.51 | 769,011.65 | 34,140.66 | 34,140.35 |
| 减:营业外支出 | 59,116.15 | 25,755.38 | 146,605.89 | 87,556.91 |
| 五、利润总额 | -171,619,375.12 | 4,442,352.14 | 12,303,605.48 | 59,195,382.11 |
| 减:所得税费用 | -25,708,743.68 | 627,085.84 | 4,513,963.7 | 10,644,364.48 |
| 六、净利润 | -145,910,631.44 | 3,815,266.3 | 7,789,641.78 | 48,551,017.63 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -145,910,631.44 | 3,815,266.3 | 7,789,641.78 | 48,551,017.63 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -143,672,969.55 | 4,663,288.16 | 14,570,990.82 | 51,859,558.43 |
| 少数股东损益 | -2,237,661.89 | -848,021.86 | -6,781,349.04 | -3,308,540.8 |
| 扣除非经常损益后的净利润 | 2,596,726.5 | 10,225,060.35 | -26,990,356.19 | -4,222,765.23 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.3 | 0.01 | 0.03 | 0.11 |
| (二)稀释每股收益 | -0.3 | 0.01 | 0.03 | 0.11 |
| 八、其他综合收益 | -797,357.78 | -400,326.58 | -707,988.21 | -431,253.9 |
| 归属于母公司股东的其他综合收益 | -797,357.78 | -400,326.58 | -707,988.21 | -431,253.9 |
| 九、综合收益总额 | -146,707,989.22 | 3,414,939.72 | 7,081,653.57 | 48,119,763.73 |
| 归属于母公司股东的综合收益总额 | -144,470,327.33 | 4,262,961.58 | 13,863,002.61 | 51,428,304.53 |
| 归属于少数股东的综合收益总额 | -2,237,661.89 | -848,021.86 | -6,781,349.04 | -3,308,540.8 |
| 公告日期 | 2026-08-24 | 2026-04-29 | 2026-03-31 | 2025-10-24 |
| 审计意见(境内) | | | 标准无保留意见 | |